Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Pound for Pound: 3 Buzzworthy Drug Stocks Worth Their Weight in Gold
09:59pm, Monday, 11'th Sep 2023
Weight-loss drugs are taking the U.S. by storm. JPMorgan Chase (NYSE: JPM ) is forecasting that the market for weight-loss medications could reach $100 billion in annual sales.
Investors May Not Have Seen the Best From Eli Lilly Stock Yet. Here's Why.
06:12am, Sunday, 10'th Sep 2023
Eli Lilly's type 2 diabetes treatment, called Mounjaro, is helping fuel new growth for the company. In addition to diabetes, Eli Lilly is looking to fast track Mounjaro for weight-loss approval by the
Analysis: Wegovy launch in UK may underline Novo's need to get ahead of Lilly
03:07am, Sunday, 10'th Sep 2023
Novo Nordisk's decision to launch its weight-loss drug Wegovy in Britain last week despite severe supply constraints may partly have been motivated by a desire to get ahead of rival Eli Lilly's own si
Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
09:19am, Saturday, 09'th Sep 2023
As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.
Only 2 Mega-Cap Monster Stocks Have Risen in Each of the Last 5 Years: Are They Buys Now?
05:52am, Saturday, 09'th Sep 2023
Of the more than 40 current mega-cap stocks, only two have generated positive returns in each of the last five years. One is a highly diversified conglomerate, while the other is a fast-growing pharma
The rise in obesity is having a massive impact on the global economy, according to Goldman Sachs. The bank estimates that obesity will drag down the world's GDP by $4 trillion in 2035.
Lilly's diabetes drug gains backing of UK watchdog -Bloomberg News
09:58pm, Thursday, 07'th Sep 2023
Eli Lilly's drug Mounjaro has won the backing of Britain's drug cost-effectiveness watchdog as a diabetes treatment, Bloomberg News reported on Thursday.
Mizuho's Jared Holz reacts to JPMorgan's huge obesity drug call
06:58pm, Thursday, 07'th Sep 2023
Jared Holz, Mizuho, joins 'Fast Money' to talk JPMorgans $100 billion call on weight loss drugs.
4 Expert Tips for Navigating a Gap Down Market
02:16pm, Thursday, 07'th Sep 2023
An Old Wall Street saying points out that investors should not “Confuse brains with a bull market.” In other words, don't get overly cocky when the market moves higher, as most stocks move higher
Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says.
11:39am, Thursday, 07'th Sep 2023
Eli Lilly and Denmark's Novo Nordisk are expected to roughly split the market for weight-loss drugs, both as diabetes and obesity treatments.
1 Weight-Loss Stock That's Been a Hotter Buy Than Eli Lilly and Novo Nordisk This Year
10:00am, Thursday, 07'th Sep 2023
Shares of WW International have been soaring this year as a result of some promising drugs. Even companies that aren't involved in making the drugs have piggybacked on the hype.
Here are the 13 stocks Jim Cramer is watching, including Eli Lilly, McDonald's
09:50am, Thursday, 07'th Sep 2023
Here are some of the tickers on my radar for Thursday, Sept. 7, taken directly from my reporter's notebook.
3 Nasdaq Stocks to Sell in September Before They Crash & Burn
08:41am, Thursday, 07'th Sep 2023
Due to what could be an unsustainable rally for equities, you may be looking for Nasdaq stocks to sell now. We've had an incredible run this year, but there are some additional indiciations that our l
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
10:00am, Tuesday, 05'th Sep 2023
Eli Lilly is making big plays in three hot markets: Alzheimer's, pain, and obesity. It's already on the cusp of getting medicines approved in those spaces.
Here's 1 Stock That Could Join Apple and Amazon in the $1 Trillion Club That You Might Have Overlooked
09:12am, Tuesday, 05'th Sep 2023
Unlike the current five stocks with $1 trillion market caps, AI isn't a major factor for this contender. Instead, its fortunes rely largely on treating diabetes, obesity, and Alzheimer's disease.
